Advanz Pharma (CXRXF) Downgraded by Zacks Investment Research
According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “
Several other analysts have also weighed in on CXRXF. Bloom Burton reissued a “hold” rating on shares of Advanz Pharma in a report on Friday, March 15th. ValuEngine raised Advanz Pharma from a “sell” rating to a “hold” rating in a report on Friday, March 1st.
Advanz Pharma Company Profile
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
Featured Story: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.